Base Therapeutics (Shanghai) Co., Ltd. clinical trial pipeline

4 trials changed in the last 30 days: 1 stopped, 3 with notable changes, 0 with minor changes only.

1. Stopped

   NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus

   Trial status changed: Not Yet Recruiting → Terminated

   Sponsor's reason: poor accrual

   Also in this update: Phase changed: not applicable → Early Phase 1; Final enrollment: 4 participants (planned 9)

   Base Therapeutics (Shanghai) Co., Ltd.·Early Phase 1· NCT07083349· Registry history of NCT07083349 on ClinicalTrials.gov (opens the registry)

   Updated Sep 30, 2026

2. Notable

   NK521 · Advanced Solid Tumors

   Primary completion pushed from Oct 2027 to Jun 2028

   Also in this update: Study completion pushed from Jul 2028 to Dec 2028

   Base Therapeutics (Shanghai) Co., Ltd.·Early Phase 1· NCT07657416· Registry history of NCT07657416 on ClinicalTrials.gov (opens the registry)

   Updated Sep 30, 2026

3. Notable

   NK510 · Gastric Cancer and Colorectal Cancer

   Recruitment opened

   Base Therapeutics (Shanghai) Co., Ltd.·Early Phase 1· NCT07166263· Registry history of NCT07166263 on ClinicalTrials.gov (opens the registry)

   Updated Oct 1, 2026

4. Notable

   NK520 · Relapsed/Refractory Acute Myeloid Leukemia

   Trial status changed: Unknown → Terminated

   Sponsor's reason: poor accrual

   Also in this update: Final enrollment: 2 participants (planned 9); Primary completion date changed from estimate of Jun 1, 2026 to Jun 1, 2025

   Base Therapeutics (Shanghai) Co., Ltd.·Early Phase 1· NCT06541444· Registry history of NCT06541444 on ClinicalTrials.gov (opens the registry)

   Updated Sep 30, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.